BMY Mar 2025 49.000 call
| Previous close | 4.2500 |
| Open | 4.4900 |
| Bid | 4.8000 |
| Ask | 4.9500 |
| Strike | 49.00 |
| Expiry date | 2025-03-21 |
| Day's range | 4.2500 - 4.4900 |
| Contract range | N/A |
| Volume | |
| Open interest | 218 |
- Yahoo Finance Video
FDA approves new Bristol Myers Squibb schizophrenia drug
Shares of Bristol Myers Squibb (BMY) are surging after the FDA approved the pharmaceutical giant's schizophrenia drug, making it the first new drug-related approach for the disease in 30 years. Market Domination Hosts Julie Hyman and Josh Lipton report more on the story and dig into how the drug works. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written and updated by Melanie Riehl
Business WireU.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
PRINCETON, N.J., September 27, 2024--U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
Barrons.comThese Stocks Moved the Most Today: Bristol Myers, Costco, EchoStar, Cassava, DJT, Wynn, HP Inc., Acadia Healthcare, and More
Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter revenue at Costco misses analysts’ estimates, and EchoStar rises on reports its Dish subsidiary is in merger talks with DirecTV.
